Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

  • Go to Emergencies.
  • Contact us:

    Campus Charité MitteInvalidenstraße 80 / Virchowweg 23
    10117 Berlin

  • Accessibility:
    Contrast Settings Change contrast
    Font size
    Font size bigger: STRG+ Font size smaller: STRG-

    You can enlarge or reduce the browser window. Please use CTRL and + to zoom in or CTRL and - to zoom out. Press CTRL and 0 to reset your browser window to normal size.

Open Menu



CCCC/DKTK.Seminar: Antitumor response to breast cancer and its implication for prognosis and treatment – Update on clinical trials and new concepts

Back to Overview

You are here:

Event for expert public only

Dear Colleagues,

It is our pleasure to cordially invite you to a special seminar with Prof. Dr. Sylvia Adams, NYU.

Antitumor response to breast cancer and its implications for prognosis and treatment – update on clinical trials and new concepts

Dr. Sylvia Adams is an Associate Professor of Medicine at the New York University School of Medicine and a Medical Oncologist caring for breast cancer patients. She completed her internal medicine training at Winthrop, her fellowship at NYU and Rockefeller University and has been on the NYU faculty for 13 years. She has expertise in immunotherapy, having led a variety of trials from NCI-sponsored investigator initiated phase I/II studies to industry-sponsored phase III FDA registration trials. She also serves on the ASCO Grants Committee and the NIH Clinical Oncology Study Section.
In her talk she will cover the topic of antitumor response to breast cancer and its implication for prognosis and treatment. In particular she will describe the history of and their composition in breast cancer, level 1 evidence of its prognostic value as biomarker in the adjuvant setting for TNBC, briefly cover TILs as predictors of response in neoadjuvant studies, show results of single agent checkpoint blockade in PD-L1+ TNBC, as well as updated results for combination studies with nab-paclitaxel and discuss her research to modify the tumor immune microenvironment in breast cancer to convert non-inflamed tumor to TIL enriched ones.

Date:    January 5, 2017
Time:    4 p.m.
Venue:  Campus Charité Mitte
Hörsaal, Institut für Pathologie
Virchowweg 15 | 10117 Berlin

Do not miss this unique opportunity to meet Prof. Dr. Adams in person and feel free to distribute this announcement to people you think would be interested.

The application for certification from the Berliner Ärztekammer is submitted and pending.

We look very much forward to welcoming you to this seminar.
Kind regards,

Prof. Dr. Ulrich Keilholz 
Komm. Direktor des
Charité Comprehensive Cancer Center  

Attendance free

Organizational and administrative matters


Prof. Dr. Sylvia Adams
Associate Professor
Department of Medicine
New York University

Event organizer



4 p.m.


Charité – Universitätsmedizin Berlin
Campus Charité Mitte
Institute of Pathology
Lecture Hall Pathology
Virchowweg 15
10117 Berlin



Back to Overview